Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1467335

Drug Profile

BI 1467335

Alternative Names: PXS 4728A

Latest Information Update: 20 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmaxis
  • Developer Boehringer Ingelheim; Pharmaxis; University of Sydney
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Eye disorder therapies; Hepatoprotectants; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic retinopathy
  • No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Renal fibrosis
  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 20 Dec 2019 Boehringer Ingelheim completes enrolment phase IIa in Diabetic retinopathy in USA (PO)
  • 18 Dec 2019 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Germany (PO)
  • 18 Dec 2019 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top